Evaluation of efficacy and safety of bevacizumab combined with paclitaxel-carboplatin chemotherapy in 44 patients with advanced non-squamous non-small cell lung cancer
10.3781/j.issn.1000-7431.2013.12.008
- Author:
Wei-Qing GU
1
Author Information
1. Department of Oncology
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
Carcinoma;
Clinical study;
Non-small cell lung;
Safety
- From:
Tumor
2013;33(12):1081-1086
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To assess the safety and efficacy of first-line bevacizumab combined with standard chemotherapy regimen in patients with advanced non-squamous non-small cell lung cancer. This report presents the result of a preplanned subanalysis of Shanghai Pulmonary Hospital's patients enrolled in SAiL study. Methods: Between July 2007 and March 2008, 44 patients with untreated locally advanced, metastatic, or recurrent non-squamous non-small cell lung cancer were recruited into this phase 4 study. Eligible patients had histologically or cytologically documented inoperable, locally advanced, metastatic, or recurrent disease (stages ?B-?); an Eastern Cooperative Oncology Group performance status score of 0-1; and adequate haematological, hepatic, and renal functions. Patients received bevacizumab (15 mg/kg every 3 weeks) plus standard chemotherapy (paclitaxel-carboplatin) every 3 weeks for up to six cycles, followed by single-agent bevacizumab until disease progression. The primary endpoint was safety, and the secondary end points included time to disease progression and overall survival. Results: The rates of clinically significant adverse events (= grade 3) of special interest were relatively low in this population (13.6%); proteinuria (7%), hypertension (2%) and bleeding (2%) were the most common adverse events. One patient died because of hemoptysis. The partial remission and stable disease rates were 52.3% (23/44) and 45.5% (20/44), respectively. One patient had progressive disease. The disease control rate was 97.7%. The median time to progression was 8.13 months, and the median overall survival was 17.73 months. Conclusion: The safety and efficacy of first-line bevacizumab-based treatment in Shanghai Pulmonary Hospital's patients with non-squamous non-small cell lung cancer is satisfying with benefits in time to progression and overall survival. There were no new safety signals to be reported. Copyright © 2013 by TUMOR.
